• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

FORGE: Focusing Ophthalmology on Reframing Glaucoma Evaluation

Article

Ophthalmologists can improve glaucoma care by evaluating the optic nerve to assess the patient's risk of progression, according to speakers at a CME symposium Saturday. Faculty members provided the audience with tips for determining disease severity through optic nerve evaluation, employing a systematic approach to the evaluation, identifying patients at risk of disease progression, and determining the most effective treatment.

New Orleans-Ophthalmologists can improve glaucoma care by evaluating the optic nerve to assess the patient's risk of progression, according to speakers at a CME symposium Saturday. Faculty members provided the audience with tips for determining disease severity through optic nerve evaluation, employing a systematic approach to the evaluation, identifying patients at risk of disease progression, and determining the most effective treatment.

Other topics included a historical overview of glaucoma diagnosis, the relationship between structure and function, optic disc and retinal nerve fiber layer examination, and the role of IOP-lowering to halt progression.

Speakers for the evening symposium, which was held at Tipitina's-The Ruins, were G.A. Cioffi, MD, Devers Eye Institute and Legacy Health System, Portland, OR; Anne L. Coleman, MD, David Geffen School of Medicine at the University of California, Los Angeles; Ronald L. Goss, MD, Baylor College of Medicine, Houston; Jeffrey M. Liebmann, MD, Manhattan Eye, Ear & Throat Hospital, New York; and Robert N. Weinreb, MD, University of California, San Diego.

The program was jointly sponsored by Ophthalmology Times and the New York Eye and Ear Infirmary and supported by an unrestricted educational grant from Allergan.

Related Videos
Paul Badawi, co-founder and CEO of Sight Sciences, chats with Neda Shamie, MD, about what drives him
© 2024 MJH Life Sciences

All rights reserved.